A phase II, non-comparative randomised trial of two treatments involving liposomal amphotericin B and miltefosine for post-kala-azar dermal leishmaniasis in India and Bangladesh
AmBisome monotherapy and combination AmBisome – miltefosine therapy for the treatment of visceral leishmaniasis in patients co-infected with HIV in India: A randomised open label, parallel arm, phase III trial
Long-term incidence of relapse and post-kala-azar dermal leishmaniasis after three different visceral leishmaniasis treatment regimens in Bihar, India
Report of the fifth post-kala-azar dermal leishmaniasis consortium meeting, Colombo, Sri Lanka, 14–16 May 2018
Impact of the visceral leishmaniasis elimination initiative on Leishmania donovani transmission in Nepal: a 10-year repeat survey
Field effectiveness of new visceral leishmaniasis regimens after 1 year following treatment within public health facilities in Bihar, India
Field safety and effectiveness of new visceral leishmaniasis treatment regimens within public health facilities in Bihar, India